Q-omics provides the consensus-scored SBSN profile across patient tissues and cancer cell-line models. SBSN expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, SBSN is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, SBSN protein abundance shows 14,447 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight MESO, COAD, and HNSC as cancer lineages where SBSN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SBSN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SBSN survival associations across molecular data types. SBSN RNA expression shows survival associations in the most cancer types (29), followed by mutation status (11) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SBSN RNA expression–survival associations across cancer types. High SBSN expression shows unfavorable associations in MESO, ACC, KIRC, OV, UVM and BRCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for SBSN RNA expression.
This table summarizes SBSN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for SBSN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SBSN shows higher tumor expression in COAD, LUSC, UCEC, LUAD, BLCA and BRCA. The COAD box plot shows higher SBSN RNA expression in tumor versus normal tissue (log2 FC = +0.236, t-test p < 0.001).
This table shows molecular features associated with SBSN in patient tissues and cancer cell lines. In patient samples, SBSN shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, SBSN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BONE.
